Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Inclusion Criteria: * Histologically/cytologically proven small cell lung cancer * Extensive disease * Measurable disease * World Health Organization (WHO) performance status 0-2 * Age 18 years or older * Normal baseline cardiac function * No prior systemic chemotherapy for small cell lung cancer * Adequate organ function including bone marrow, kidney, and liver * No history of interstitial lung disease or pulmonary fibrosis * No history of prior malignancy unless patient has been disease free for greater than 5 years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix * No pregnancy or breast feeding; patients of child-bearing potential must agree to use an appropriate method of contraception * Written informed consent before randomization Exclusion criteria: * Pre-existing peripheral neuropathy (greater than Grade 1, CTCAE version 3.0) * Uncontrolled or severe cardiovascular disease * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule